Related articles

Your scans may look clear, but are you really in the clear?
After surgery, chemotherapy, or radiation, many cancer survivors undergo routine CT, MRI, or tumor marker tests. When results come back “normal,” it’s a huge relief—but can also lead to a false sense of security.
In truth, numerous studies suggest that microscopic cancer cells may still linger in the body—dormant, hidden, and waiting for the right conditions to reactivate. This is why post-cancer monitoring needs to go beyond conventional imaging, and why emerging tools like those developed by RGCC offer deeper insight into real-time recurrence risk.

For many cancer patients, follow-up often means regularly scheduled CT or MRI scans, hoping to catch signs of recurrence early. But what if these imaging tools are only showing part of the picture? In truth, most imaging technologies only detect tumors once they’ve reached a certain size. When it comes to predicting whether cancer will return—or whether it might develop in the first place—conventional scans may not tell the whole story.
This is where newer tools, such as Onco-D-clare by RGCC, provide added value. Rather than detecting cancer that has already formed, this test evaluates your internal risk profile on a genetic and molecular level. It’s a proactive way to personalize your prevention strategy.

Why RGCC CTC Testing May Reveal the Hidden Risks Still Lurking in Your Body
For many people, the end of cancer treatment marks the end of their journey—often celebrated as a full recovery. But the truth is, cancer doesn’t always end when chemotherapy, surgery, or radiation do. Research increasingly shows that small numbers of cancer cells may remain dormant in the body, quietly waiting for the right moment to resurface. This is why, even years after completing treatment, patients can still face recurrence or metastasis.
So how can we detect these “invisible threats” that evade standard tests? This is exactly where RGCC CTC (Circulating Tumor Cell) testing comes in—a cutting-edge tool designed to identify residual cancer activity before it becomes a visible problem.

When we talk about early cancer detection, most people think of imaging tests or tumor markers.
These tools are valuable for identifying structural abnormalities or elevated markers — in other words, when a disease has already begun to manifest.
But what if you could go one step earlier?
Before anything is visible or measurable, is there a way to understand your underlying genetic risk?

Have you ever had a health checkup that came back “normal,” yet you still felt fatigued, foggy, or out of balance?
Or known someone who was diagnosed with cancer shortly after receiving clear test results?
These situations highlight a crucial gap:
Traditional checkups are important—but they focus on detecting existing issues, not predicting future risks.

You may regularly undergo health checkups, including cancer markers and imaging scans.
Yet, it’s not uncommon to hear of individuals being diagnosed with cancer shortly after receiving “normal” test results. Why does this happen?
The truth is, traditional screenings, while essential, have their limitations.
Some risks remain hidden—undetectable by standard scans or blood markers—because they originate at a cellular or molecular level, far before tumors form.
This is where RGCC (Research Genetic Cancer Centre) testing plays a unique and valuable role.